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Abstract 
Objectives: To establish how the terms recommended by the European Commission to 
describe side effect risk in patient information leaflets (PILs) influences expectations of side 
effects, and to identify factors associated with these side effect expectations.  
Design: A cross-sectional online survey was carried out by a market research company.  
Setting: Data were collected in England between 18th March and 1st April 2016. 
Participants: 1003 adults aged between 18 and 65.  
Main outcome measures: Self-reported expectation that the described side effects would 
affect participants if they took the medicine, measured on a likelihood scale from 1 (very 
unlikely) to 5 (very likely).   
Results: Participants formed high expectations of side effects for ‘Very common’ and 
‘Common’ side effects, with 51.9% and 45.0% of participants rating these as ‘very likely’ or 
‘likely’ to happen to them, respectively. This fell to 8.1% for ‘Uncommon’, 5.8% for ‘Rare’ 
and 4.1% for ‘Very rare’. For each descriptor, higher expectations of side effects were more 
associated with women or being from an ethnic minority, or having less education, a 
household illness, high perceived sensitivity to medicines, or negative beliefs about 
medicines.  
Discussion: The current use of verbal descriptors to communicate side effect risk in PILs 
leads to high side effect expectations. These expectations could contribute to nocebo induced 
medication side effects experienced by patients. Additional work is required to identify ways 
to improve the way risk information is conveyed in PILs.   
Key words: expectations, side effects, patient information leaflets, risk, descriptors 
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How does the side effect information in patient information leaflets 
influence people’s side effect expectations? A cross-sectional national 
survey of 18 to 65 year olds in England.  
 Introduction 
Medications may generate adverse reactions, with studies showing that around 6.5% of 
patient admissions to hospitals are related to an adverse drug reaction (ADR) 1. ADRs are 
noxious, unintended responses to medication which occur at normal doses 2. Medication side 
effects such as these can significantly reduce patient adherence 3 often leading to reduced 
therapeutic benefit for the patient. They also mean financial costs for health services as they 
are a major cause of hospital admissions, and emergency department and outpatient care 
visits 4.  
Not all side effects are related to the physiological action of the medication, however 5. For 
example it has been noted that only 10.9% of adverse reactions reported to common 
prescription drugs are clearly attributable to the medication 6. Many other, non-specific, side 
effects  may occur due to a nocebo effect 7. Nocebo effects have been described as the flip-
side to the placebo effect, whereby an adverse reaction is experienced by someone who 
receives an inert exposure 8. From a recent systematic review we know that expectations such 
as those generated from verbal suggestions of what symptoms to expect are one of the 
strongest factors affecting the development of nocebo effects 9. Expectations have also been 
found to contribute to the side effects that patients experience from their medications 10,11. 
This is a problem as side effects are an important cause of patient non-adherence 3,12. 
One of the main ways that patients can generate these negative expectations of their 
medication is by reading the accompanying patient information leaflet (PIL). Over 70% of 
patients will read the accompanying PIL for a newly prescribed medication 13. In Europe, all 
medicines prescribed or sold over-the-counter must be distributed with a comprehensive PIL 
14. In 1998, European Commission (EC) guidelines advised PILs should group side effects 
according to five frequency bands, using a different verbal label for each one 15. As such side 
effects could be grouped into ‘very common’ (affect more than 1 in 10 patients), ‘common’ 
(up to 1 in 10), ‘uncommon’ (up to 1 in 100), ‘rare’ (up to 1 in 1000), or ‘very rare’ (up to 1 
in 10,000). 
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However, since the guidelines were published, several studies have shown that these verbal 
labels are problematic, leading to overestimations by samples of students, patients and health 
care professionals 16-23.  As such current guidelines suggest combining verbal and frequency 
expressions (e.g. ‘very common, more than 1 in 10 people’) 24. Although it has been shown 
that this may not lead to more accurate side effect risk estimates than the verbal format 25 and 
still leads to significant risk overestimations when compared to numerical frequency bands 
alone 26. In part, patient estimations seem to depend on the type of side effect with ‘mild’ side 
effects generally resulting in higher estimations than ‘severe’ side effects 19. 
Although previous studies have looked at how these verbal descriptors affect people’s 
numerical estimation of side effects, they have not looked at how they affect people’s 
subsequent expectations of side effects. The two issues are linked, but not identical. It is 
possible for an optimistic patient to believe that symptoms are common but unlikely to affect 
them personally, and vice versa. This is important as it is these expectations that may trigger 
a nocebo response. This study investigated people’s expectations of side effects when 
described using EC recommended descriptors. We also tested whether these expectations are 
associated with demographic and psychological characteristics such as beliefs about 
medicines, optimism or perceived sensitivity to medicines which have previously been 
implicated in the nocebo literature 5,27. 
Our specific aims were to: 
1. Assess people’s expectations of side effects from the EC recommended risk descriptors  
2. Investigate if these expectations differ depending on whether they relate to mild or severe 
side effects. 
3. Determine whether demographic factors (age, gender, ethnicity, employment status, level 
of education, or presence of a household illness) are associated with the expectation of 
experiencing a side effect after taking a medicine labelled with one of the EC recommended 
risk descriptors.  
4. Determine whether psychological factors (optimism, perceived sensitivity to medicines, 
belief about medicines, health anxiety, health literacy, or PIL reading behaviour) are 
associated with the expectation of experiencing a side effect after taking a medicine labelled 
with one of the EC recommended risk descriptors. 
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5. Determine if participants’ understanding of what the verbal descriptors mean is associated 
with their subsequent expectations of side effects. 
 Methods 
2.1 Design 
The market research company Ipsos MORI conducted an online survey of adults aged 
between 18 and 65 living in England on our behalf, between 18th March and 1st April 2016. 
This study was approved by the Psychiatry, Nursing and Midwifery Research Ethics 
Committee at King’s College London (ref: HR-15/16-2104). 
The same study was used to assess in detail factors associated with how patients understand 
the numerical risk information conveyed by verbal labels of risk, the results of which have 
been submitted elsewhere.  
2.2 Participants 
Participants were recruited by Ipsos MORI using their existing database of people living in 
England and interested in taking part in internet surveys (approximate n=160,000). We 
excluded over 65s because of  concerns about the representativeness of this group in internet 
surveys 28,29. Potential participants were emailed a link to the survey. After providing 
informed consent, participants were allocated by the survey software to receive questions 
about either mild or severe side effects. The allocation was based on which condition had the 
lowest number of completed responses at that time. Panel participants received points for 
completing the survey equivalent to 75 pence. 
2.3 Sample size 
We used quotas based on the National Readership Survey 30 to ensure that the sample 
reflected the demographic profile of 18 to 65 year olds in England. This is standard method 
for this form of research to ensure samples are representative of the adult English population. 
These quotas were based on participant age and gender (interlocked), location, and working 
status. A priori we intended to recruit 1,000 participants to provide us with a sample error of 
about plus or minus 3%.  
2.4 Questionnaire development 
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Where possible, we included or adapted items that had been previously developed and tested 
for their reliability and validity, and that have been widely used in the literature. Using 
opportunity sampling we piloted all items with five members of the general public who read 
through the questionnaire with the researcher and identified anything that was not clear. We 
rephrased items where necessary to improve clarity.  
2.5 Primary outcome: Side effect expectations 
Five items were used to assess participant expectations of side effects. Depending on which 
condition they had been assigned to, participants were told that a new drug had been 
developed with either ‘dizziness’ or ‘kidney failure’ as one of its side effects. The side effect 
was described using each of the five EC recommended combined verbal and frequency 
expressions (e.g. very common, may affect more than 1 in 10 people) which were presented 
in a random order. Participants were asked to rate how likely they were to experience 
dizziness or kidney failure if they took the drug on a five point scale ranging from ‘very 
unlikely to very likely’. 
2.6 Demographic factors 
Participants were asked about their: age, gender, ethnicity, highest level of education, 
employment status and whether they or anyone in their household had a long-standing illness, 
disability or infirmity. 
2.7 Psychological factors 
A single item to assess health literacy was adapted from elsewhere 31 and asked participants 
to state how often they needed help reading patient information leaflets. We also included 
one question which asked how often participants read patient information leaflets when 
taking a new medication. Response options for both ranged from one (‘never’) to five 
(‘always’). We assessed health anxiety using one question from the health anxiety inventory 
32. This asked participants to rate themselves from 1 “I do not worry about my health” to 4 “I 
spend most of my time worrying about my health”.  
The Revised Life Orientation Test 33 was used to rate participant optimism. This has six 
questions and provides a score from 5 (least optimism) to 30 (most optimism).  We used the 
overuse and harm general subscales from the Beliefs about Medicines Questionnaire (BMQ) 
34 to measure attitudes towards medicines in general. These subscales give scores from 5 to 
20, with higher scores indicating higher perceived overuse or harm. The Perceived Sensitivity 
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to Medicines scale 35 was used to assess how sensitive participants thought they were to 
medicines. This provides a score from 5 to 25 with higher scores indicating higher sensitivity. 
2.8 Participant understanding of verbal risk descriptors  
We included 5 items (presented in a random order) to assess participant understanding of the 
side effect risk descriptors (‘very common’, ‘common’, ‘uncommon’, ‘rare’ and ‘very rare’). 
These asked people to consider a PIL for an imaginary drug which stated, for example, that 
“nausea is common.” Participants were asked to estimate how many out of 10,000 people 
who take the drug would develop that side effect. Participants were asked about either mild 
side effects (‘headache’ or ‘nausea’) or severe side effects (‘seizure’ or ‘difficulty breathing’) 
depending on which condition they had been assigned to.  .  
2.9 Analysis 
Participants’ expectations were grouped by likelihood to see the frequency that each 
likelihood statement was selected for the different risk descriptors. We carried out a series of 
chi-squared tests to see if participant expectations differed between mild and severe side 
effects. For occurrences where the expected cell count was below 5, Fisher’s exact test was 
used instead. 
Ordinal regressions were carried out to identify if any demographic or psychological 
characteristics, or how well participants estimated the EC recommended descriptors, were 
associated with expectations of personally experiencing side effects. The dependent variable 
for each regression was participants’ scores on the likelihood scale for each verbal descriptor. 
For each regression, all demographic variables and side effect type (mild or severe) were 
added in one block, and each psychological variable was added on its own, controlling for the 
previously entered variables.  
For all analyses, answers of ‘don’t know’ or ‘prefer not to say’ were excluded. Only 3% of 
participants answered ‘don’t know’, and 1% answered ‘prefer not to say’ for any question 
where this was an option. Analyses were carried out using SPSS 22. As participant 
expectations did not change by more than 0.2% when using data weighted by age, gender, 
region and working status, our analyses used unweighted data. 
 Results 
3.1 Sample characteristics 
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1003 participants completed the survey and were included in the final sample (see Figure 1 
for response rates). Demographic information for the participants is given in Table 2.  
3.2 The influence of the EC recommended combined risk descriptors on 
participant expectations 
Table 1 shows participant expectations of side effects for each of the descriptors. 
Expectations of side effects varied widely for each descriptor, however the majority of 
participants thought that ‘Very common’ and ‘Common’ side effects were very likely or 
likely to happen to them (51.9% and 45% respectively) despite these terms only being 
intended to represent a risk of around 1 in 10 patients being affected. Expectations of side 
effects dropped substantially for ‘Uncommon’, ‘Rare’ and ‘Very rare’ with 8.1%, 5.8 % and 
4.1% of participants thinking there were very likely or likely to experience the side effects 
respectively. 
3.3 Does the severity of the side effect affect participant expectations? 
The difference in expectations between mild and severe side effects is shown in Table 1. 
There was no difference in expected likelihood between mild and severe side effects except 
for side effects described as ‘rare’ in which expectations were lower for mild versus severe 
side effects, p = .003.  
3.4 Are demographic factors associated with expectations?  
Table 2 shows the association between demographic variables and perceived likelihood of 
experiencing side effects, with all demographic variables controlled for each other. Men were 
31% less likely than women to have higher expectations of side effects described as being 
‘very common’ or ‘common’. Participants from ethnic minorities were more likely to have 
higher expectation of side effects being as ‘common, uncommon, rare and very rare’.  
Compared to those with a university degree, participants with no academic qualifications 
were more likely to have a higher expectation of side effects described as ‘uncommon, rare 
and very rare’. Similarly compared to having a university degree, participants with school 
qualifications were more likely to have a higher expectation of side effects described as 
‘uncommon, rare and very rare’. Having an illness or an illness in the household increased 
expectations of side effects compared to having no household illness but this was only 
significant for some of the descriptors (‘very common,’ ‘common,’ and ‘uncommon’).  
3.5 Are psychological factors associated with expectations? 
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Table 2 shows the association between psychological variables and perceived likelihood of 
experiencing side effects, controlling for demographic characteristics. People with a higher 
perceived sensitivity to medicines were 5 to 10% more likely to have higher expectations of 
side effects described using each of the descriptors compared to those with a lower perceived 
sensitivity to medicines. Participants who thought medicines were overused or caused harm 
were 5 to 10%, and 7 to 20% respectively more likely to have higher expectations of side 
effects described as ‘common’, ‘uncommon’, ‘rare’ or ‘very rare’. Participants scoring higher 
on health anxiety were 25% more likely to have higher expectations of side effects described 
as ‘very common’ compared to those with lower health anxiety. Participants who needed help 
reading patient information leaflets were 14 to 49% more likely to have higher expectations 
of side effects described as ‘common’, ‘uncommon’, ‘rare’ and ‘very rare’. Participants who 
read PILs more often were 12% less likely to have higher expectations of side effects 
described as ‘very rare’ compared to those who read PILs less often. There was no effect of 
optimism on participants’ side effect expectations. 
3.6 Are participants’ numerical estimates of the risk descriptors associated with 
their subsequent side effect expectations? 
Whether participants estimated each of the EC recommended descriptors in accordance with 
the corresponding EC frequency band had little effect on their side effect expectations, apart 
from the descriptor ‘very rare’ and ‘uncommon’. Participants who overestimated the number 
of patients likely to experience a ‘very rare’ side effect  were 45% less likely to have higher 
expectations of ‘very rare’ side effects, and participants who underestimated the intended 
meaning of ‘uncommon’ were 54% more likely to have higher expectations of uncommon 
side effects. Full results of participants’ estimations have been submitted elsewhere. 
 Discussion  
4.1 Summary of main findings and interpretation 
There are several key findings from our work. First, when presented with the standard format 
of side effect risk information that is currently used in PILs, people form high expectations 
about their personal likelihood of experiencing symptoms, with the majority of people 
thinking ‘very common’ or ‘common’ side effects are likely to happen to them, despite those 
descriptors only representing a risk of around 1 in 10 people being affected. However, these 
expectations are formed independently from probability estimates. Under, over or correctly 
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estimating the numerical meaning of a side effect risk descriptor had little bearing on whether 
a patient felt that they, personally, would experience it. These high side effect expectations 
are problematic, as they can be an important precursor to the development of actual side 
effects, as a result of a nocebo effect9. Although reading about side effects does not always 
cause someone to experience a side effect 36,37, in some situations it can 10,11. Therefore it is 
important to reduce any unrealistically high side effect expectations that PILs produce.  
Second, similar to the nocebo literature9, participants’ expectation of side effects described 
using the current guidelines do show associations with demographic and psychological 
factors. This will allow clinicians to be aware of those patients more at risk of developing 
nocebo induced side effects to their medications as a result of high side effect expectations. 
Women are more likely to expect higher risk side effects compared to Men, and people from 
ethnic minorities are more likely to expect side effects than people who are White. This 
supports previous research that has shown women and people from ethnic minorities have 
more dread of potential risks/hazards in general 38. Participants with no academic 
qualifications and those with school qualifications are more likely to expect lower risk side 
effects than those with university degrees. This may be because these participants are less 
familiar with and have difficulty interpreting the terms ‘1 in 1000’ and ‘1 in 10,000’ that 
accompanied the verbal descriptors in these questions and therefore misinterpret what it 
means in terms of their personal side effect expectations. Similarly higher health illiteracy 
was associated with higher expectations of side effects. Having a household illness increased 
expectations of side effects compared to not having a household illness, possibly due to an 
availability heuristic 39 as symptoms are more likely to be present if there is a household 
illness. Interestingly despite being implicated in the literature on people’s numerical estimates 
of the descriptors 19, we found side effect type had little effect on participants’ expectations. 
Similarly whether participants provided correct or incorrect risk estimates for the descriptors 
had little effect on expectations. There are two possible explanations for this. First the verbal 
risk descriptors do not influence expectations. Or second, the inclusion of the numerical 
expression draws people’s attention away from the verbal risk descriptor. Either way the 
verbal risk descriptors are ineffective at influencing people’s expectations. These support the 
view that participants form independent expectations of side effects from any generalised, 
numerical risk estimates.   
In terms of the psychological factors perceived sensitivity to medicines showed the strongest 
association with expectation; participants with a higher perceived sensitivity were more likely 
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to expect side effects than those with a lower perceived sensitivity. In addition a stronger 
belief that medicines are overused and cause harm increased the expected likelihood of side 
effects. This supports previous research showing negative views about medicines translate 
into negative expectations 5. Perceived sensitivity to medicines and negative belief about 
medicines have also been found to determine side effect reporting to vaccinations and new 
medication40,41. It is likely that the relationship between these factors and symptom reporting 
is mediated by negative expectations. It may be important to combat these negative 
medication beliefs in the first instance to reduce patients experiencing nocebo induced side 
effects as a result of negative expectations.  
4.2 Implications for side effect reporting guidelines and clinical practice  
Verbal descriptors have long been favoured for the presentation of side effect risk 
information 42. However, previous research including our own large scale survey (submitted 
elsewhere) has shown that verbal descriptors mislead rather than inform, leading readers to 
greatly overestimate the risk of side effects.  Given that our analyses in this paper suggest that 
participant estimations of the currently used descriptors also have little if any impact on 
patient expectations of their own likelihood of experiencing side effects, the rationale for 
using them appears to be weak. As well as having implications for PILs, our results also 
highlight the need for clinicians to assess patients’ understanding of the side effect 
information and the risk of side effects occurring, before explaining the likelihood of side 
effects based on information in PILs and providing reassurance to patients if necessary. This 
is particularly important for patients with risk factors for over-estimating their likelihood of 
developing side effects, namely: women, those with lower educational attainment, those with 
a household illness, those who seem to have difficulty reading health-related literature, those 
with a perceived sensitivity to medicine, and negative beliefs about the overuse and harm of 
medicine. 
4.3 Strength and weaknesses, and future research 
This study included a large sample size of 18 to 65 year olds in the English population, 
specifically recruited to demographically reflect the composition of the English population on 
multiple key variables (age, gender, location, and working status). Whether members of 
market research panels are psychologically representative of the general population in terms 
of attitudes to medicines and their expectations of side effects is unknown, however. In 
addition because we were interested in participants’ perceptions of verbal descriptors rather 
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than side effects, and also to avoid confusing participants when they came to answer our 
primary outcome questions we chose to use different side effects to assess participants’ 
understanding of the descriptors than those used in the primary side effect expectations 
outcome. It is plausible that had we used the same symptom in the estimation measure we 
would have identified stronger associations with our primary outcome. 
Many questions used in the survey were hypothetical, asking participants to state their 
expectations of side effects for an imaginary drug, for example. Future research could 
usefully build on this study by testing whether the findings hold true for patients given a 
newly prescribed medication. Due to the hypothetical nature, despite research showing there 
is some evidence that previous experience influences nocebo effects 9, we could not assess 
participants’ previous experience with this imaginary drug. We did however include the 
perceived sensitivity to medicines measure which assessed participants’ past reactions to 
medicines in general, and therefore acted as a proxy measure of participants’ experience of 
side effects in the past. We excluded over 65s due to issues of how representative they are in 
online surveys. However over 65s are the heaviest medication consumers 43, therefore 
replicating this work within that population would be of use. It may also be useful for future 
research to break down ethnicity into more than two categories, to see if any further 
differences lie within the ‘ethnic minority’ category. Not only this there is a possibility that 
risk information also affects the perceived benefits, as well as side effects of a medication, as 
such future work in these field should consider both forms of outcome. 
Finally we suggest that future research should explore ways of reducing participant 
expectations of side effects. Previous research has shown that presenting side effect risk with 
numerical expressions versus verbal labels (e.g. 1 in 10 versus common) results in lower 
expectations 16. Another method may be to reframe the numerical risk of side effects in terms 
of the number/proportion of people who remain side effect free (e.g. 9 in 10 people will not 
experience) 44. Alternatively, it may be better to use figurative risk representations that 
visually display the risk of side effects. This has been shown to improve comprehension and 
accuracy of side effect risk interpretation when displayed alongside numerical risk formats 17. 
 Conclusion 
Members of the public commonly overestimate their own personal likelihood of developing 
the side effects referred to in PILs using the current risk descriptors. This is especially true 
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for women, ethnic minorities, those less educated, those with a household illness and those 
who have a higher perceived sensitivity to medicines, and negative beliefs about medicines. 
Interestingly, however, how someone interprets a risk descriptor has little bearing on whether 
they expect to develop side effects themselves.  Further research is necessary in order to 
provide sufficient evidence to reach a conclusion about what should be done regarding verbal 
descriptors.  In the meantime health care professionals should take care to correct any 
unrealistic expectations patients may have about medication side effects to allow patients to 
make properly informed decisions about medication and to reduce the likelihood of nocebo 
effects.  
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 Tables/Figures 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:  
Eligibility check was used to confirm participants’ age in case this had changed since they were 
emailed the link 
* Completing the survey too quickly to have given genuine, considered answers, or providing 
identical answers to five or more consecutive questions where this was possible.   
 
 
 
 
 
11,657 people listed as age 
18-65 were emailed the 
study link
1155 clicked on study link
9 dropped out upon reading 
the information sheet
1146 gave consent and 
examined for eligibility
37 were excluded due to 
being identified as 
‘speeding or 
straightlining’*
10,502 did not respond
1144 confirmed eligible 
and started survey 
1040 completed the survey
2 dropped out during 
eligibility check 
1003 included in the final 
sample
104 dropped out during 
survey 
Figure 1. Participant flow through the survey 
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Table 1. Expected likelihood of minor (dizziness) and severe (kidney failure) side effects 
from an imagined new drug using the EC recommended combined descriptors.  
Note: Chi-square analyses did not include participants who answered ‘Don’t know’ 
* One cell had an expected cell count of less than 5 so Fisher’s exact was used instead 
 
 
Current guidelines Expectancy Mild, n (%) Severe, n (%) Total, n (%) 
Very Common 
(more than 1 in 10) 
Very likely 115 (22.7) 106 (21.3) 221 (22.0) 
Likely 152 (30.0) 148 (29.8) 300 (29.9) 
About as likely as not 118 (23.3) 128 (25.8) 246 (24.6) 
Unlikely 91 (18.0) 79 (15.9) 170 (16.9) 
Very unlikely 20 (4.0) 20 (4.0) 40 (4.0) 
Don’t know 10 (2.0) 16 (3.2) 26 (2.6) 
Chi square test p 
Common 
(up to 1 in 10) 
Very likely 58 (11.5) 63 (12.7) 121 (12.1) 
Likely 175 (34.6) 155 (31.2) 330 (32.9) 
About as likely as not 122 (24.1) 132 (26.6) 254 (25.3) 
Unlikely 121 (23.9) 114 (22.9) 235 (23.4) 
Very unlikely 20 (4.0) 19 (3.8) 39 (3.9) 
Don’t know 10 (2.0) 14 (2.8) 24 (2.4) 
Chi square test p  
Uncommon 
(up to 1 in 100) 
Very likely 7 (1.4) 10 (2.0) 17 (1.7) 
Likely 32 (6.3) 32 (6.4) 64 (6.4) 
About as likely as not 92 (18.2) 103 (20.7) 195 (19.4) 
Unlikely 215 (42.5) 217 (43.7) 432 (43.1) 
Very unlikely 154 (30.4) 121 (24.3) 275 (27.4) 
Don’t know 6 (1.2) 14 (2.8) 20 (2.0) 
Chi square test p  
Rare 
(up to 1 in 1,000) 
Very likely 3 (0.6) 7 (1.4) 10 (1.0) 
Likely 28 (5.5) 20 (4.0) 48 (4.8) 
About as likely as not 56 (11.1) 72 (14.5) 128 (12.8) 
Unlikely 136 (26.9) 169 (34.0) 305 (30.4) 
Very unlikely 278 (54.9) 218 (43.9) 496 (49.5) 
Don’t know 5 (1.0) 11 (2.2) 16 (1.6) 
Chi square test p  
Very Rare 
(up to 1 in 10,000) 
Very likely 5 (1.0) 6 (1.2) 11 (1.1) 
Likely 15 (3.0) 15 (3.0) 30 (3.0) 
About as likely as not 38 (7.5) 51 (10.3) 89 (8.9) 
Unlikely 65 (12.8) 70 (14.1) 135 (13.5) 
Very unlikely 375 (74.1) 342 (68.8) 717 (71.5) 
Don’t know 8 (1.6) 13 (2.6) 21 (2.1) 
Chi square test p  
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Table 2. Demographic and psychological factors associated with participant expectations that very common, common, uncommon, rare and very 
rare side effects would personally affect them.  
Variable No (%) or 
median (IQR) 
Very common 
Adjusted odd ratios (95% 
CI) n = 977 
Common 
Adjusted odd ratios (95% 
CI) n = 979 
Uncommon 
Adjusted odd ratios (95% 
CI) n = 983 
Rare 
Adjusted odd ratios (95% 
CI) n = 987 
Very rare 
Adjusted odd ratios (95% 
CI) n = 982 
Gendera       
Male 492 (49.1%) 0.69 (0.46 to 0.92) 0.69 (0.55 to 0.87) 1.05 (0.83 to 1.33) 0.88 (0.69 to 1.12) 0.94 (0.70 to 1.25) 
Female 511 (50.9%) Reference Reference Reference Reference Reference 
Agea 41.0 (22.0) 0.99 (0.98 to 1.00) 1.00 (0.99 to 1.01) 0.99 (0.98 to 1.002) 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01) 
Ethnicitya       
Ethnic minorities 107 (10.7%) 1.25 (0.86 to 1.83) 1.49 (1.02 to 2.18) 2.09 (1.42 to 3.07) 2.06 (1.41 to 3.03) 2.33 (1.53 to 3.56) 
White 886 (88.3%) Reference Reference Reference Reference Reference 
Employmenta       
Not working 280 (27.9%) 1.07 (0.81 to 1.39) 1.01 (0.78 to 1.32) 1.02 (0.78 to 1.33) 0.90 (0.68 to 1.19) 0.79 (0.56 to 1.10) 
Working 723 (72.1%) Reference Reference Reference Reference Reference 
Educationa       
No academic qualifications 44 (4.4%) 0.82 (0.47 to 1.46) 1.23 (0.69 to 2.20) 3.06 (1.70 to 5.51) 2.73 (1.52 to 4.92) 4.88 (2.62 to 9.06) 
School qualifications 387 (38.6%) 0.94 (0.74 to 1.19) 0.99 (0.77 to 1.25) 1.42 (1.11 to 1.81) 1.52 (1.18 to 1.96) 1.55 (1.14 to 2.10) 
University degree 565 (56.3%) Reference Reference Reference Reference Reference 
Household illnessa       
Yes - me 290 (28.9%) 1.27 (0.97 to 1.66) 1.40 (1.07 to 1.83) 1.42 (1.07 to 1.87) 1.13 (0.85 to 1.50) 1.23 (0.88 to 1.71) 
Yes- someone else 128 (12.9%) 1.47 (1.04 to 2.10) 1.78 (1.25 to 2.54) 1.85 (1.29 to 2.65) 1.17 (0.81 to 1.70) 1.06 (0.68 to 1.65) 
No 571 (56.9%) Reference Reference Reference Reference Reference 
Side effect typea       
Mild 506 (50.4%) 1.03 (0.82 to 1.29) 1.00 (0.80 to 1.26) 0.80 (0.63 to 1.12) 0.70 (0.55 to 0.89) 0.77 (0.58 to 1.03) 
Severe 497 (49.6%) Reference Reference Reference Reference Reference 
Estimates 1b       
Incorrect (under for Very     
  common, over for Very rare) 
- 0.83 (0.63 to 1.10) - - - 0.55 (0.37 to 0.83) 
Correct - Reference - - - Reference 
Estimates 2b       
Under - - 0.94 (0.60 to 1.48) 1.54 (1.10 to 2.16) 1.29 (0.79 to 2.09) - 
Over - - 0.96 (0.70 to 1.33) 1.25 (0.95 to 1.64) 1.08 (0.80 to 1.46) - 
Correct - - Reference Reference Reference - 
Optimismb 19.0 (6.0) 0.98 (0.95 to 1.00) 0.98 (0.96 to 1.01) 0.97 (0.95 to 1.001) 0.98 (0.95 to 1.00) 0.98 (0.95 to 1.02) 
Perceived sensitivity to medicinesb 10.0 (6.0) 1.05 (1.02 to 1.08) 1.05 (1.02 to 1.08) 1.07 (1.04 to 1.10) 1.10 (1.07 to 1.14) 1.10 (1.07 to 1.14) 
BMQ overuseb 12.0 (4.0) 1.04 (1.00 to 1.08) 1.05 (1.01 to 1.09) 1.08 (1.04 to 1.12) 1.05 (1.01 to 1.09) 1.08 (1.03 to 1.14) 
BMQ harmb 10.0 (4.0) 1.04 (1.00 to 1.08) 1.07 (1.03 to 1.12) 1.14 (1.10 to 1.19) 1.17 (1.12 to 1.22) 1.20 (1.13 to 1.26) 
Healthy anxietyb 2.0 (0.0) 1.25 (1.02 to 1.53) 1.13 (0.93 to 1.39) 1.14 (0.93 to 1.40) 0.98 (0.79 to 1.20) 1.07 (0.84 to 1.37) 
Health illiteracyb 1.0 (1.0) 1.06 (0.94 to 1.20) 1.14 (1.004 to 1.29) 1.44 (1.27 to 1.63) 1.49 (1.31 to 1.69) 1.47 (1.28 to 1.68) 
PIL reading frequencyb 4.0 (2.0) 1.00 (0.91 to 1.11) 0.97 (0.87 to 1.07) 0.96 (0.86 to 1.06) 0.96 (0.86 to 1.07) 0.88 (0.78 to 0.999) 
Note:  
a Controlled for each other, b Controlled for variablesa, IQR = Interquartile range, CI = Confidence interval, BMQ = Belief about Medicines, PIL = Patient information leaflet, bold = p < .05, N 
≠ 1003 due to excluding ‘don’t know’ or ‘prefer not to say’ responses. 
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 Supplemental material 
Topline results 
 
 Results are based on all respondents (1,003) unless otherwise stated.  
 Where percentages do not sum to 100, this may be due to respondents being able to select multiple responses, 
computer rounding or the exclusion of ‘don’t know’/ not stated. 
 An asterisk (*) represents a value of less than half or one percent, but greater than zero. 
 The response rate for this survey was 9% (1,003 responses from 11,657 people that the link was emailed to). 
 115 participants ended the survey without completing it (and were not included in the data); 37 people were 
excluded from the data due to being identified as ‘speeding’ or straightlining’; i.e. completing the survey too quickly 
to have given genuine, considered answers, or providing identical answers to five or more consecutive questions 
where this was possible.   
Q1. Please type in your age: 
 % 
18-24 15 
25-34 22 
35-44 21 
45-54 22 
55-65 20 
 
Q2. Which gender do you identify yourself with? 
 
 % 
Male 50 
Female 50 
 
Q3. In which of the following regions do you live? 
 
    % 
North East 5 
North West 13 
Yorkshire and Humberside 10 
West Midlands 10 
East Midlands 8 
East of England 11 
South West 10 
South East 16 
London 17 
 
Q4. Which of the following best describes your employment status?                                                                                                                    
 
    % 
Working – full time (30 or more hours a week) 48 
Working – part-time (less than 30 hours a week) 17 
Self-employed 7 
Unemployed – looking for a job 5 
Unemployed – not looking for a job/long-term sick 
or disabled/Housewife/husband/Full-time carer 
12 
Retired 7 
Pupil/Student/In full-time education 5 
NET: Working 72 
NET: Not working 28 
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Q7a. A new drug has been developed that has headache as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
 
“Headache is uncommon” 
 
Imagine 10,000 people take the drug. Out of these people, how many do you think will get a headache? 
 
 % 
0 * 
1 - 100 46 
101 - 500 22 
501 - 1,000 16 
1,001 - 2,500 9 
2,501 - 5,000 4 
5,001 – 7,500 1 
7,501 – 10,000 2 
Mean 766.1 
Base: All in split sample A (506) 
 
Q8a. A new drug has been developed that has headache as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
 
“Headache is very common” 
 
Imagine 10,000 people take the drug. Out of these people, how many do you think will get a headache? 
 
 % 
0 0 
1 - 100 7 
101 - 500 4 
501 - 1,000 5 
1,001 - 2,500 4 
2,501 - 5,000 13 
5,001 – 7,500 20 
7,501 – 10,000 47 
Mean 6249 
Base: All in split sample A (506) 
 
Q16a. A new drug has been developed that has nausea as one of its listed side effects. The patient information 
leaflet accompanying the drug states that: 
 
“Nausea is rare” 
 
Imagine 10,000 people take the drug. Out of these people, how many do you think will get nausea? 
 % 
0 * 
1 - 100 60 
101 - 500 22 
501 - 1,000 12 
1,001 - 2,500 3 
2,501 - 5,000 2 
5,001 – 7,500 0 
7,501 – 10,000 1 
Mean 455.8 
Base: All in split sample A (506) 
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Q18a. A new drug has been developed that has nausea as one of its listed side effects. The patient information 
leaflet accompanying the drug states that: 
“Nausea is very rare”  
 
Imagine 10,000 people take the drug. Out of these people, how many do you think will get nausea? 
 
 % 
0 * 
1 - 100 70 
101 - 500 19 
501 - 1,000 8 
1,001 - 2,500 1 
2,501 - 5,000 1 
5,001 – 7,500 * 
7,501 – 10,000 1 
Mean 331.9 
Base: All in split sample A (506) 
 
Q19a. A new drug has been developed that has nausea as one of its listed side effects. The patient information 
leaflet accompanying the drug states that: 
“Nausea is common”  
 
Imagine 10,000 people take the drug. Out of these people, how many do you think will get nausea? 
 
 % 
0 1 
1 - 100 5 
101 - 500 4 
501 - 1,000 8 
1,001 - 2,500 6 
2,501 - 5,000 22 
5,001 – 7,500 23 
7,501 – 10,000 31 
Mean 5425.6 
Base: All in split sample A (506) 
 
Q24a. A new drug has been developed that has dizziness as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
“Dizziness is very common (may affect more than 1 in 10 people)” 
 
How likely do you think it is that you personally would experience dizziness if you took the drug? 
 
    % 
Very likely 23 
Likely 30 
About as likely as not 23 
Unlikely 18 
Very unlikely 4 
Don’t know 2 
Base: All in split sample A (506) 
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Q25a. A new drug has been developed that has dizziness as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
 
“Dizziness is common (may affect up to 1 in 10 people)” 
 
How likely do you think it is that you personally would experience dizziness if you took the drug? 
 
    % 
Very likely 11 
Likely 35 
About as likely as not 24 
Unlikely 24 
Very unlikely 4 
Don’t know 2 
Base: All in split sample A (506) 
 
Q26a. A new drug has been developed that has dizziness as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
“Dizziness is uncommon (may affect up to 1 in 100 people)” 
 
How likely do you think it is that you personally would experience dizziness if you took the drug? 
 
    % 
Very likely 1 
Likely 6 
About as likely as not 18 
Unlikely 43 
Very unlikely 30 
Don’t know 1 
Base: All in split sample A (506) 
 
 
Q27a. A new drug has been developed that has dizziness as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
 
“Dizziness is rare (may affect up to 1 in 1000 people)” 
 
How likely do you think it is that you personally would experience dizziness if you took the drug? 
 
    % 
Very likely 1 
Likely 6 
About as likely as not 11 
Unlikely 27 
Very unlikely 55 
Don’t know 1 
Base: All in split sample A (506) 
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Q28a. A new drug has been developed that has dizziness as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
 
“Dizziness is very rare (may affect up to 1 in 10,000 people)” 
 
How likely do you think it is that you personally would experience dizziness if you took the drug? 
 
    % 
Very likely 1 
Likely 3 
About as likely as not 8 
Unlikely 13 
Very unlikely 74 
Don’t know 2 
Base: All in split sample A (506) 
 
Q7b. A new drug has been developed that has difficulty breathing as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
 
“Difficulty breathing is uncommon” 
 
Imagine 10,000 people take the drug. Out of these people, how many do you think will have difficulty 
breathing? 
 
 % 
0 1 
1 - 100 57 
101 - 500 21 
501 - 1,000 10 
1,001 - 2,500 7 
2,501 - 5,000 3 
5,001 – 7,500 * 
7,501 – 10,000 2 
Mean 655.5 
Base: All in split sample B (497) 
 
Q8b. A new drug has been developed that has difficulty breathing as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
 
“Difficulty breathing is very common”  
 
Imagine 10,000 people take the drug. Out of these people, how many do you think will have difficulty 
breathing? 
 
 % 
0 1 
1 - 100 12 
101 - 500 8 
501 - 1,000 8 
1,001 - 2,500 6 
2,501 - 5,000 13 
5,001 – 7,500 18 
7,501 – 10,000 35 
Mean 5044.8 
 
Base: All in split sample B (497) 
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Q16b. A new drug has been developed that has seizures (fits) as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
“Seizures (fits) are rare”  
 
Imagine 10,000 people take the drug. Out of these people, how many do you think will have a seizure (fit)? 
 
 % 
0 1 
1 - 100 71 
101 - 500 16 
501 - 1,000 6 
1,001 - 2,500 3 
2,501 - 5,000 1 
5,001 – 7,500 0 
7,501 – 10,000 2 
Mean 413.2 
Base: All in split sample B (497) 
 
Q18b. A new drug has been developed that has seizures (fits) as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
 
“Seizures (fits) are very rare”  
 
Imagine 10,000 people take the drug. Out of these people, how many do you think will have a seizure (fit)? 
 
 % 
0 1 
1 - 100 84 
101 - 500 9 
501 - 1,000 3 
1,001 - 2,500 2 
2,501 - 5,000 1 
5,001 – 7,500 0 
7,501 – 10,000 1 
Mean 233.3 
Base: All in split sample B (497) 
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Q19b. A new drug has been developed that has seizures (fits) as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
 
“Seizures (fits) are common”  
 
Imagine 10,000 people take the drug. Out of these people, how many do you think will have a seizure (fit? 
 
 % 
0 * 
1 - 100 16 
101 - 500 9 
501 - 1,000 10 
1,001 - 2,500 6 
2,501 - 5,000 21 
5,001 – 7,500 18 
7,501 – 10,000 21 
Mean 4171.6 
Base: All in split sample B (497) 
 
 
Q24b. A new drug has been developed that has kidney failure as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
“Kidney failure is very common (may affect more than 1 in 10 people)” 
 
How likely do you think it is that you personally would experience kidney failure if you took the drug? 
 
    % 
Very likely 21 
Likely 30 
About as likely as not 26 
Unlikely 16 
Very unlikely 4 
Don’t know 3 
Base: All in split sample B (497) 
 
Q25b. A new drug has been developed that has kidney failure as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
 
“Kidney failure is common (may affect up to 1 in 10 people)” 
 
How likely do you think it is that you personally would experience kidney failure if you took the drug? 
 
    % 
Very likely 13 
Likely 31 
About as likely as not 27 
Unlikely 23 
Very unlikely 4 
Don’t know 3 
Base: All in split sample B (497) 
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Q26b. A new drug has been developed that has kidney failure as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
“Kidney failure is uncommon (may affect up to 1 in 100 people)” 
 
How likely do you think it is that you personally would experience kidney failure if you took the drug? 
 
    % 
Very likely 2 
Likely 7 
About as likely as not 21 
Unlikely 44 
Very unlikely 24 
Don’t know 3 
Base: All in split sample B (497) 
 
Q27b. A new drug has been developed that has kidney failure as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
 
“Kidney failure is rare (may affect up to 1 in 1000 people)” 
 
How likely do you think it is that you personally would experience kidney failure if you took the drug? 
 
    % 
Very likely 1 
Likely 4 
About as likely as not 14 
Unlikely 34 
Very unlikely 44 
Don’t know 2 
Base: All in split sample B (497) 
 
 
Q28b. A new drug has been developed that has kidney failure as one of its listed side effects. The patient 
information leaflet accompanying the drug states that: 
 
“Kidney failure is very rare (may affect up to 1 in 10,000 people)” 
 
How likely do you think it is that you personally would experience kidney failure if you took the drug? 
 
    % 
Very likely 1 
Likely 3 
About as likely as not 10 
Unlikely 14 
Very unlikely 69 
Don’t know 3 
Base: All in split sample B (497) 
 
Q29. How often, if at all, do you need to have someone help you when you read instructions, pamphlets, or 
other written material from your doctor or pharmacy? 
    % 
Never 64 
Rarely 21 
About half the time 8 
Often 4 
Always 3 
Don’t know 2 
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Q30. When you take new medications how often, it at all do you read the patient information leaflet 
accompanying them? 
    % 
Never 2 
Rarely 15 
About half the time 19 
Often 23 
Always 39 
Don’t know 2 
 
Q32. The following are things that other people have said about medicines in general. Please indicate the 
extent to which you agree or disagree with each statement by ticking the appropriate box. 
There are no right or wrong answers. We are interested in your personal views.  
 
1. Doctors use too many medicines 
 
 % 
Strongly disagree 4 
Disagree 22 
Uncertain 36 
Agree 30 
Strongly agree 7 
 
2. People who take medicines should stop their treatment for a while every now and again 
 % 
Strongly disagree 15 
Disagree 28 
Uncertain 37 
Agree 17 
Strongly agree 3 
 
3. Most medicines are addictive 
 % 
Strongly disagree 16 
Disagree 42 
Uncertain 28 
Agree 12 
Strongly agree 2 
 
4. Natural remedies are safer than medicines  
 % 
Strongly disagree 11 
Disagree 25 
Uncertain 45 
Agree 15 
Strongly agree 4 
 
5. Medicines do more harm than good 
 % 
Strongly disagree 20 
Disagree 46 
Uncertain 27 
Agree 6 
Strongly agree 1 
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6. All medicines are poisons  
 % 
Strongly disagree 26 
Disagree 37 
Uncertain 23 
Agree 11 
Strongly agree 3 
 
7. Doctors place too much trust on medicines  
 % 
Strongly disagree 6 
Disagree 27 
Uncertain 33 
Agree 28 
Strongly agree 7 
 
8. If doctors had more time with patients they would prescribe fewer medicines  
 % 
Strongly disagree 3 
Disagree 14 
Uncertain 34 
Agree 39 
Strongly agree 10 
 
Q33. Please indicate how far you agree with each statement by ticking the appropriate box. Be as honest as 
you can throughout, and try not to let your responses to one question influence your response to other 
questions. There are no right or wrong answers.  
 
1. In uncertain times, I usually expect the best 
 
 % 
Strongly disagree 6 
Disagree 25 
Neutral 42 
Agree 25 
Strongly agree 3 
 
2. It’s easy for me to relax 
 
 % 
Strongly disagree 7 
Disagree 22 
Neutral 26 
Agree 39 
Strongly agree 7 
 
 
 
3. If something can go wrong for me, it will 
 
 % 
Strongly disagree 6 
Disagree 32 
Neutral 33 
Agree 23 
Strongly agree 7 
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4. I’m always optimistic about my future 
 
 % 
Strongly disagree 5 
Disagree 18 
Neutral 33 
Agree 38 
Strongly agree 6 
 
5. I enjoy my friends a lot 
 
 % 
Strongly disagree 1 
Disagree 5 
Neutral 22 
Agree 52 
Strongly agree 20 
 
6. It’s important for me to keep busy 
 
 % 
Strongly disagree 2 
Disagree 9 
Neutral 28 
Agree 49 
Strongly agree 13 
 
7. I hardly ever expect things to go my way 
 
 % 
Strongly disagree 7 
Disagree 32 
Neutral 34 
Agree 21 
Strongly agree 7 
 
8. I don’t get upset too easily 
 
 % 
Strongly disagree 7 
Disagree 22 
Neutral 32 
Agree 33 
Strongly agree 7 
 
9. I rarely count on good things happening to me 
 
 % 
Strongly disagree 7 
Disagree 28 
Neutral 34 
Agree 25 
Strongly agree 6 
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10. Overall, I expect more good things to happen to me than bad 
 
 % 
Strongly disagree 5 
Disagree 14 
Neutral 34 
Agree 38 
Strongly agree 9 
 
Q34. Please read each of the statements carefully and then select the one which best describes your feelings, 
over the past six months.  
 
 % 
I do not worry about my health 15 
I occasionally worry about my health 71 
I spend much of my time worrying about my health 12 
I spend most of my time worrying about my health 3 
 
Q35. These are some things other people have said when prescribed medication during regularly scheduled 
and patient-requested visits. Please indicate to what extent, if at all, you agree or disagree with each statement.  
 
1. My body is very sensitive to medicines 
 
 % 
Strongly disagree 23 
Disagree 45 
Uncertain 22 
Agree 9 
Strongly agree 2 
 
2. My body overreacts to medicines 
 
 % 
Strongly disagree 27 
Disagree 47 
Uncertain 19 
Agree 5 
Strongly agree 1 
 
3. I usually have stronger reactions to medicines than most people 
 
 % 
Strongly disagree 27 
Disagree 45 
Uncertain 20 
Agree 7 
Strongly agree 1 
 
4. I have had a bad reaction to medicines in the past 
 
 % 
Strongly disagree 24 
Disagree 37 
Uncertain 11 
Agree 21 
Strongly agree 6 
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5. Even very small amounts of medicines can upset my body 
 
 % 
Strongly disagree 26 
Disagree 45 
Uncertain 18 
Agree 9 
Strongly agree 2 
 
Q36. Which of the following ethnic groups would you describe yourself as belonging to?  
 
 % 
White – English/Welsh/Scottish/Northern Irish/British 83 
White – Irish 1 
White – Gypsy or Irish Traveller 1 
White – Any other background 4 
Mixed or multiple ethnic groups – White and Black Caribbean 1 
Mixed or multiple ethnic groups – White and Black African 1 
Mixed or multiple ethnic groups – White and Asian * 
Mixed or multiple ethnic groups – Any other mixed/multiple 
ethnic background 
1 
Asian or Asian British – Indian 3 
Asian or Asian British – Pakistani 1 
Asian or Asian British – Bangladeshi 1 
Asian or Asian British – Chinese 1 
Asian or Asian British – Any other Asian background 1 
Black, African, Caribbean or Black British – African 1 
Black, African, Caribbean or Black British – Caribbean 1 
Black, African, Caribbean or Black British – Any other 
Black/African/Caribbean background 
1 
Other ethnic group – Arab * 
Other ethnic group – Any other ethnic group * 
Prefer not to say 1 
NET: White  88 
NET: BME 11 
 
Q37. Please state the highest level of education you have achieved.  
 
 % 
Left school without qualifications 5 
Secondary education (O-level/GCSE/A-level) 39 
Higher education (BSc/BA/higher qualification) 56 
Prefer not to say 1 
 
 
Q38. Do you, or anyone else in your household have any long-standing illness, disability or infirmity?  
 
 % 
Yes – myself 29 
Yes – someone else in my household 13 
No 57 
Prefer not to say 1 
 
 
